Myriad Genetics First Quarter 2024 Financial Earnings

Tuesday, May 7, 2024 | 1:30pm PST / 4:30pm EST

Watch the webcast Download presentation

Events & Presentations

  • 45th Annual Global Goldman Sachs Global Healthcare Conference

    06/12/2024 | 12:20pm PDT / 3:20pm EDT

    Watch the webcast

  • Leerink Partners Healthcare Crossroads Conference

    05/30/2024 | 8:00am PDT / 11:00am EDT

    Watch the webcast

  • Piper Sandler Virtual Cancer Testing Day

    05/21/2024 | 8:00am PDT / 11:00am EDT

    Watch the webcast
View all events

Financial Reports and Filings

Date Filing Title Downloads
06/10/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/07/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/07/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/07/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/07/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/07/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/07/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/07/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
06/06/2024 8-K Report of unscheduled material events or corporate event RTF XLS PDF HTML XBRL
06/04/2024 4 Statement of changes in beneficial ownership of securities RTF XLS PDF HTML XBRL
View all filings

Latest News

What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk Thumbnail

What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk

Jul 17, 2024 | Products

Read more
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing Thumbnail

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

Jul 11, 2024 | Products

Read more
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date Thumbnail

Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Jul 09, 2024 | Products

Read more
View all news releases

Our commitment to social responsibility

At Myriad, social responsibility plays an important role in our approach to discovering and delivering valuable, transformative diagnostic tests across all major diseases to improve patients’ lives.

Learn more about the actions we’re taking in ESG

Read our ESG report
“As a leader in genetic testing and precision medicine, we understand the important role we play in advancing health equity and social justice. We also recognize our responsibility to operate in harmony with the environment which includes efforts to minimize our impact on the climate. These topics are directly linked with our purpose and values. We are proud to release our second annual environmental, social, and governance (ESG) report."

— Paul Diaz
President and CEO of Myriad Genetics

Our commitment to social responsibility

At Myriad, social responsibility plays an important role in our approach to discovering and delivering valuable, transformative diagnostic tests across all major diseases to improve patients’ lives.

Learn more about the actions we’re taking in ESG

Read our ESG report
“As a leader in genetic testing and precision medicine, we understand the important role we play in advancing health equity and social justice. We also recognize our responsibility to operate in harmony with the environment which includes efforts to minimize our impact on the climate. These topics are directly linked with our purpose and values. We are proud to release our second annual environmental, social, and governance (ESG) report."

— Paul Diaz
President and CEO of Myriad Genetics